BR112022003670A2 - Métodos de tratamento - Google Patents

Métodos de tratamento

Info

Publication number
BR112022003670A2
BR112022003670A2 BR112022003670A BR112022003670A BR112022003670A2 BR 112022003670 A2 BR112022003670 A2 BR 112022003670A2 BR 112022003670 A BR112022003670 A BR 112022003670A BR 112022003670 A BR112022003670 A BR 112022003670A BR 112022003670 A2 BR112022003670 A2 BR 112022003670A2
Authority
BR
Brazil
Prior art keywords
treatment
treatment methods
tumors
pde1
certain cancers
Prior art date
Application number
BR112022003670A
Other languages
English (en)
Inventor
Peng Li
Robert Davis
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of BR112022003670A2 publication Critical patent/BR112022003670A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos de tratamento. a divulgação refere-se à combinação de inibidores de fosfodiesterase 1 (pde1) úteis para o tratamento de certos cânceres ou tumores, tais como câncer de cólon. em outra forma de realização, a divulgação refere-se ao uso de inibidores de pde1 e um agente antitumoral opcional para o tratamento de certos cânceres ou tumores.
BR112022003670A 2019-09-03 2020-09-03 Métodos de tratamento BR112022003670A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962895476P 2019-09-03 2019-09-03
PCT/US2020/049248 WO2021046250A1 (en) 2019-09-03 2020-09-03 Methods of treatment

Publications (1)

Publication Number Publication Date
BR112022003670A2 true BR112022003670A2 (pt) 2022-05-24

Family

ID=74853030

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003670A BR112022003670A2 (pt) 2019-09-03 2020-09-03 Métodos de tratamento

Country Status (11)

Country Link
US (1) US20220354851A1 (pt)
EP (1) EP4025218A4 (pt)
JP (1) JP2022546711A (pt)
KR (1) KR20220054853A (pt)
CN (1) CN114340636A (pt)
AU (1) AU2020343329A1 (pt)
BR (1) BR112022003670A2 (pt)
CA (1) CA3147071A1 (pt)
IL (1) IL290983A (pt)
MX (1) MX2022002607A (pt)
WO (1) WO2021046250A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157926B1 (en) * 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
IL260933B2 (en) * 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Preparations containing tocorsol or its analogues
SG11202001664VA (en) * 2017-08-31 2020-03-30 Abbvie Inc Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
US20220072003A1 (en) * 2019-01-07 2022-03-10 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
CA3147071A1 (en) 2021-03-11
EP4025218A4 (en) 2023-05-31
KR20220054853A (ko) 2022-05-03
IL290983A (en) 2022-05-01
CN114340636A (zh) 2022-04-12
JP2022546711A (ja) 2022-11-07
EP4025218A1 (en) 2022-07-13
AU2020343329A1 (en) 2022-03-24
WO2021046250A1 (en) 2021-03-11
US20220354851A1 (en) 2022-11-10
MX2022002607A (es) 2022-03-25

Similar Documents

Publication Publication Date Title
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2022001718A (es) Combinaciones de cabozantinib y atezolizumab para tratar cancer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
MX2018005461A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2020006297A (es) Variantes de cd19.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
AU2018380132A8 (en) Tubulin inhibitors
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase